Biotron is developing first-in-class drugs to serious viral diseases. Its lead compound BIT225 is in Phase 2 trials for treatment of HIV and Hepatitis C virus.
Location: Australia, New South Wales, Sydney
Investors 2
| Date | Name | Website |
| 01.06.2024 | Significan... | significan... |
| 19.06.2024 | Significan... | significan... |
Mentions in press and media 1
| Date | Title | Description |
| 25.11.2021 | Biotron Drug Effective Against COVID-19 In Animals | BIT225 administered orally significantly reduced viral load in the lungs and blood of animals challenged with SARS-CoV-2. BIT225 protected against severe disease, indicated by the significant prevention of body weight loss in animals treate... |